Compugen Establishes Small Molecule Drug Discovery Subsidiary

06-Jul-2004

Compugen Ltd. announced the establishment of a new subsidiary, Keddem Bioscience Ltd., focused on small molecule drug discovery. The program now being transferred to the new company was initiated in 2000 as the chemistry division of Compugen. The subsidiary's offices and laboratories are located in Ashkelon, Israel.

Keddem's objective is to dramatically improve the success rate for the development of new drug products by developing and applying a technology platform that consistently enables the design of small molecule modulators for potentially any given protein target. Relevant targets may include difficult or intractable targets, such as protein-protein interactions, many of which are considered well validated but have so far been beyond the reach of conventional practices.

Identifying a lead chemical for a potential target is a long and arduous undertaking, considered by many to be the limiting factor in drug development. Common methods for finding such molecules, typically variants of high-throughput screening of drug-like compounds or protein structure-based drug design, suffer from low success rates and often fail to find any candidate compound for a given target.

The Keddem approach is based on the proposed creation of a comprehensive, yet relatively small set of carefully designed molecules and a suite of algorithms. The set will consist of less than 100,000 molecules, mostly novel compounds that differ in several ways from molecules in existing screening libraries. Although 100,000 compounds is a small number compared to the millions typically used in screening libraries of drug-like compounds, the Keddem screening set is designed to be truly exhaustive, covering the relevant chemical space, and so should be equally applicable to all targets.

When synthesized, the Keddem set of molecules will be used in a screening process, with a functional assay for the target of interest. Utilizing a suite of algorithms to analyze the screening results, the platform is designed to provide comprehensive three-dimensional information about the active site of the target. This information then enables the design of a variety of potent inhibitors satisfying desired drug-like properties.

"This initiative is another example of the power in bringing the capabilities of physics, mathematics, and computer science to the disciplines underlying pharmaceutical research," stated Mor Amitai, Ph.D., President and Chief Executive Office of Compugen Ltd. "We are very pleased that this activity has now matured to the point where establishing it as a separate company provides the best opportunity to fulfill its significant potential. At the same time," Dr. Amitai continued, "similar to our decision to establish Evogene as our agbio subsidiary, this enables Compugen to maintain its focus on predictive biology and on the creation and use of discovery engines for new therapeutic proteins and diagnostic markers."

Keddem's current research team consists of professionals from the fields of physics, mathematics, chemistry, and biochemistry. The Company is managed by Dr. Dror Ofer and Dr. Arnon Levy.

Other news from the department manufacturing

These products might interest you

Whatman™ folded filter papers

Whatman™ folded filter papers by Cytiva

Whatman folded filter papers

Convenient folded formats speed up your sample preparation

filter papers
Systec H-Series

Systec H-Series by Systec

Safe, reproducible and validatable sterilization of liquids, solids and waste

Autoclaves with 65-1580 liters usable space, flexibly expandable for various applications

laboratory autoclaves
Loading...

Most read news

More news from our other portals

So close that even
molecules turn red...